Literature DB >> 20881042

Peptide inhibitors of flavivirus entry derived from the E protein stem.

Aaron G Schmidt1, Priscilla L Yang, Stephen C Harrison.   

Abstract

Peptides derived from the "stem" of dengue virus (DV) type 2 (DV2) envelope (E) protein inhibit DV2 infectivity, targeting a late-stage fusion intermediate. We show here that stem peptides from all DV serotypes cross-inhibit DV1 to DV4 but that corresponding peptides derived from related flaviviruses do not. This failure to inhibit infection is not due to poor interaction with the E protein but rather to loss of association with the virion membrane. Residues 442 to 444 of the stem are determinants of inhibition; increasing hydrophobicity in this region increases inhibitory strength. These results support a two-step model of how stem-derived peptides inhibit viral entry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20881042      PMCID: PMC3004314          DOI: 10.1128/JVI.01440-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  T-Coffee: A novel method for fast and accurate multiple sequence alignment.

Authors:  C Notredame; D G Higgins; J Heringa
Journal:  J Mol Biol       Date:  2000-09-08       Impact factor: 5.469

2.  Structures of immature flavivirus particles.

Authors:  Ying Zhang; Jeroen Corver; Paul R Chipman; Wei Zhang; Sergei V Pletnev; Dagmar Sedlak; Timothy S Baker; James H Strauss; Richard J Kuhn; Michael G Rossmann
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

3.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

4.  Role of HIV membrane in neutralization by two broadly neutralizing antibodies.

Authors:  S Munir Alam; Marco Morelli; S Moses Dennison; Hua-Xin Liao; Ruijun Zhang; Shi-Mao Xia; Sophia Rits-Volloch; Li Sun; Stephen C Harrison; Barton F Haynes; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

5.  Viral entry inhibitors targeted to the membrane site of action.

Authors:  Matteo Porotto; Christine C Yokoyama; Laura M Palermo; Bruce Mungall; Mohamad Aljofan; Riccardo Cortese; Antonello Pessi; Anne Moscona
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

6.  Structure of the dengue virus envelope protein after membrane fusion.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Nature       Date:  2004-01-22       Impact factor: 49.962

7.  Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence.

Authors:  E A Henchal; M K Gentry; J M McCown; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1982-07       Impact factor: 2.345

8.  A ligand-binding pocket in the dengue virus envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-20       Impact factor: 11.205

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation.

Authors:  Stéphane Bressanelli; Karin Stiasny; Steven L Allison; Enrico A Stura; Stéphane Duquerroy; Julien Lescar; Franz X Heinz; Félix A Rey
Journal:  EMBO J       Date:  2004-02-12       Impact factor: 11.598

View more
  36 in total

Review 1.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

2.  Mutational analysis of the zippering reaction during flavivirus membrane fusion.

Authors:  Karen Pangerl; Franz X Heinz; Karin Stiasny
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

3.  Dynamics and binding interactions of peptide inhibitors of dengue virus entry.

Authors:  Diyana Mohd Isa; Sek Peng Chin; Wei Lim Chong; Sharifuddin M Zain; Noorsaadah Abd Rahman; Vannajan Sanghiran Lee
Journal:  J Biol Phys       Date:  2019-01-24       Impact factor: 1.365

Review 4.  The continued threat of emerging flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Nat Microbiol       Date:  2020-05-04       Impact factor: 17.745

5.  Structure of a dengue virus envelope protein late-stage fusion intermediate.

Authors:  Daryl E Klein; Jason L Choi; Stephen C Harrison
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

6.  Chemoproteomic profiling identifies changes in DNA-PK as markers of early dengue virus infection.

Authors:  Michael L Vetter; Mary A Rodgers; Matthew P Patricelli; Priscilla L Yang
Journal:  ACS Chem Biol       Date:  2012-10-02       Impact factor: 5.100

Review 7.  Novel approaches to flavivirus drug discovery.

Authors:  Carolyn Botting; Richard J Kuhn
Journal:  Expert Opin Drug Discov       Date:  2012-03-22       Impact factor: 6.098

8.  Membrane-tethered mucin-like polypeptides sterically inhibit binding and slow fusion kinetics of influenza A virus.

Authors:  Corleone S Delaveris; Elizabeth R Webster; Steven M Banik; Steven G Boxer; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-26       Impact factor: 11.205

Review 9.  Flaviviruses: braking the entering.

Authors:  Theodore C Pierson; Margaret Kielian
Journal:  Curr Opin Virol       Date:  2013-01-24       Impact factor: 7.090

10.  Cross-inhibition of chikungunya virus fusion and infection by alphavirus E1 domain III proteins.

Authors:  Claudia Sánchez-San Martín; Soumya Nanda; Yan Zheng; Whitney Fields; Margaret Kielian
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.